Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Inclusion Criteria

• •Females aged ≥ 18 years.
• •Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
• •Low, Middle tumor burden and high tumor burden with cPCI score ≤ 12 based on pre-operative CT or PET/CT examination
• •Complete cytoreduction can be achieved based on CT or PET/CT examination
• •Patients must agree to undergo BRCA (breast cancer gene) and HRD (homologous recombination deficiency) testing
• •Performance status (ECOG 0-2)
• •Adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery:
• •1. white blood cells \>3,000/µL, absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL,
• •2. serum creatinine \<1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL/min according to Cockroft-Gault formula or to local lab measurement,
• •3. serum bilirubin \<1.25 x UNL, AST(SGOT) and ALT(SGPT) \<2.5 x UNL.
• •Comply with the study protocol and follow-up.
• •Patients who have given their written informed consent.